While humans can ultimately adjust to many severe physical impediments, loss of vision is devastating to anyone. The need to intervene effectively confronts ophthalmological drug developers with an array of targets in a highly complex and immensely sensitive organ that is protected against external agents, including drugs. Ocular disorders are not only disease of advanced age and lifestyle, but also a field with a wide range of unmet medical need.

Cambridge Healthtech Institute’s third annual conference on Targeting Ocular Disorders provides a platform to discuss the challenges, achievements and perspectives in ophthalmological pharmacology. A large array of novel drug targets and therapies from simple antibiotics and anti-inflammatory drugs to retinoids and monoclonal antibodies as well as siRNA strands and gene therapy will be covered. The latest pipeline of drugs in research-driven companies in Phase I and Phase II will be showcased. The event will aim to cover a broad range of diseases including but not limited to glaucoma, dry eye syndrome and allergic conjunctivitis in the anterior segment and age-related and diabetic macular degeneration, retinopathy and retinitis pigmentosa in the posterior segment of the eye.

Who should attend: Scientists, managers, directors and executives from pharma, biotech, academia and CROs working in ocular drug discovery and development. Researchers developing pharmacological and drug delivery mechanisms in highly innovative companies, integrated ophthalmology and eye care specialist companies, global pharmaceutical companies, CROs, technology providers and investors.

Topics will include, but are not limited to: 

  • Novel targets, pathways and mechanisms of action
    • Anti VEGF, Rho Kinase and ROCK inhibitors, beta blockers, cholingergics, CAIs
    • Gene therapy/cell therapy
  • Supporting technologies and preclinical models
    • Ophthalmic imaging and analysis tools
    • Relevant animal models
    • Nanoparticles and other ocular drug delivery methods
  • Clinical Trial case studies and promising drugs in the pipeline (Phase I and Phase II)
    • Posterior diseases: age-related and diabetic macular degeneration, retinopathy
    • Anterior diseases: glaucoma, dry eye syndrome, allergic conjunctivitis

If you are interested in speaking, click here to submit a speaking proposal.

The deadline for submission is March 11, 2015. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For questions or suggestions about the meeting, please contact:
Amid Zand
Associate Conference Producer
Cambridge Healthtech Institute
T: (+1) 781-972-1346
E: azand@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Submit A Speaker Proposal 

Part Of DOT